Genzyme clinical trials

Acquired by Sanofi, Apr 4, 2011 · source ↗

The registry lists 308 studies whose lead sponsor is Genzyme. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 308. List all 308 → · All Sanofi studies →

• International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registryRecruitingNCT00358943

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Fabry Disease Registry & Pregnancy Sub-registryRecruitingNCT00196742

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Pompe Disease Registry ProtocolRecruitingNCT00231400

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Pompe Pregnancy Sub-RegistryRecruitingNCT00567073

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDRecruitingNCT06666413Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXCompletedNCT03754790Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BCompletedNCT03974113Phase 2/3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active, not recruitingNCT05164055Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedNCT03368664Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionActive, not recruitingNCT02843035Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• LEMTRADA Pregnancy Registry in Multiple SclerosisCompletedNCT03774914

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Mucopolysaccharidosis I (MPS I) RegistryCompletedNCT00144794

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive, not recruitingNCT03019406Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2TerminatedNCT04221451Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedNCT00410761Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male SubjectsCompletedNCT05238714Phase 1

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• China Post-marketing Surveillance (PMS) Study of Aldurazyme®CompletedNCT05134571Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Study of Lademirsen (SAR339375) in Patients With Alport SyndromeTerminatedNCT02855268Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• China Post-marketing Surveillance (PMS) Study of Fabrazyme®CompletedNCT05054387Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa TreatmenCompletedNCT04676373Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedNCT02201108Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedNCT00418886Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerCompletedNCT01945762

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyCompletedNCT02004691Phase 2/3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid CancerCompletedNCT01876784Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyCompletedNCT02004704Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or BCompletedNCT02554773Phase 1/2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male ParticipantsCompletedNCT06421714Phase 1

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerCompletedNCT00537095Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Study of the Effects of Fabrazyme Treatment on Lactation and InfantsTerminatedNCT00230607Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe DiseaseCompletedNCT02782741Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Pompe Lactation Sub-RegistryCompletedNCT00566878

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Avalglucosidase Alfa Extension StudyCompletedNCT02032524Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed InfantsTerminatedNCT00418821Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.CompletedNCT01898364Phase 1

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisCompletedNCT03549871Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD PatientsTerminatedNCT03523728Phase 2/3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Growth and Development Study of Alglucosidase AlfaCompletedNCT00486889Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 StudiesCompletedNCT02536755Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular GoiterCompletedNCT00454220Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00042341Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationTerminatedNCT02906020Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668CompletedNCT02313285

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study of RG-012 in Subjects With Alport SyndromeCompletedNCT03373786Phase 1

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Effect of Venglustat in Patients With Renal ImpairmentCompletedNCT03687554Phase 1

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the KneeCompletedNCT02845271Phase 2

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa TreatmentCompletedNCT03687333Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• Immune Tolerance Induction StudyTerminatedNCT00701701Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted before Genzyme became part of Sanofi

• Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe DiseaseCompletedNCT01410890Phase 4

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi

• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3

  Sponsor listed in the registry: Genzyme, a Sanofi Company · First submitted after Genzyme became part of Sanofi